Phenothiazine Compounds for Diamond Blackfan Anemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for Diamond-Blackfan anemia (DBA) and other ribosomal disorders are limited, with corticosteroids providing only temporary relief and bone marrow transplantation being risky and not suitable for all patients.
Innovation Solution
Development of novel phenothiazine compounds that inhibit calmodulin activity, which can be used to treat DBA and other ribosomal disorders by promoting erythroid cell production and reducing p53 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are used to treat DBA, then initial response is achieved in 80% of patients, but efficacy wanes over time and chronic use causes side effects
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of phenothiazine compounds (varying substituents R1-R6, n, m, p parameters) to optimize calmodulin binding affinity and duration of action, creating compounds with sustained therapeutic effects that overcome the transient efficacy of corticosteroids
Solution Approach 2:
The patent introduces calmodulin as an intermediary target - phenothiazine compounds bind to calmodulin to inhibit its function, thereby indirectly regulating p53 activity and promoting erythroid progenitor cell survival. This intermediary mechanism provides sustained therapeutic effect unlike direct corticosteroid action
2Reliability
If bone marrow transplantation is performed to cure DBA, then hematologic manifestation is cured, but substantial morbidity and mortality occur and suitable donors are limited
Solution Approach 1:
The patent employs small-molecule phenothiazine compounds as disposable, non-invasive therapeutic agents that can be administered orally or systemically without requiring invasive procedures like bone marrow transplantation. These compounds provide sustained therapeutic effect through continuous calmodulin inhibition
Solution Approach 2:
The patent enables the body's own erythroid progenitor cells to recover and function properly through calmodulin inhibition, allowing endogenous blood cell production to resume without requiring external donor cells. The compounds facilitate self-repair of the hematologic system
3Quantity of substance
If chronic blood transfusion is used to maintain DBA patients, then anemia is managed, but iron overload develops in organs
Solution Approach 1:
The patent enables the body to produce its own hemoglobin through stimulation of endogenous erythroid progenitor cells via calmodulin inhibition, eliminating the need for external blood transfusions and preventing iron overload from chronic transfusion therapy
Data Source
AI summary
The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).